Search clinical trials for: Impaired Hepatic Function

Total 27668 results

Cassava Sciences, Inc.

Not yet recruiting

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Hepatic Insufficiency
Eli Lilly and Company

Recruiting

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Hepatic Insufficiency | Healthy

United States
Eli Lilly and Company

Recruiting

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Hepatic Insufficiency | Healthy

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Esophageal Cancer | Advanced Solid Tumor

China
Johannes Gutenberg University Mainz
Interdisciplinary Center Clinical Trials (IZKS), University Medical Center...

Recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function (CaboCHILD)

Hepatocellular Carcinoma

Germany
GlaxoSmithKline

Recruiting

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13)

Multiple Myeloma

Greece, Korea, Republic of, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

Hepatocellular Carcinoma | Cirrhosis | Cholangiocarcinoma | Metastatic Malignant Neoplasm in the Liver

United States
Eli Lilly and Company

Completed

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

Hepatic Insufficiency | Healthy

United States
Tang-Du Hospital

Completed

Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function

Hepatic Cancer

China
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

Hepatic Insufficiency | Healthy

United States
Boehringer Ingelheim

Completed

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

Hepatic Insufficiency | HIV Infections

France, United States, Spain
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Eli Lilly and Company

Completed

A Study of Tirzepatide in Participants With Impaired Liver Function

Hepatic Insufficiency

United States
Bayer

Completed

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

United States
Jazz Pharmaceuticals

Completed

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Hepatic Impairment

United States
Sanofi

Terminated

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

Korea, Republic of, Germany
Chimerix

Completed

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Hepatic Impairment

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

Hepatic Insufficiency

Hungary, Czechia, Slovakia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
UCB Biopharma S.P.R.L.

Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Impaired Hepatic Function | Healthy Study Participants

United States
Shire

Completed

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

Healthy | Hepatic Impairment

United States
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

Germany, Belgium, Lithuania, United States, Bulgaria, Romania
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Diabetic Kidney Disease

United States
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

Rheumatoid Arthritis

United States, Germany, New Zealand
Gilead Sciences

Completed

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Nonalcoholic Steatohepatitis (NASH) | Primary Sclerosing Cholangitis (PSC)

United States, New Zealand
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Healthy Subjects | Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Hepatic Impairment | Solid Tumors

Belgium, Germany, Netherlands, Italy, Singapore, United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Alcoholism | Hepatic Cirrhosis

Germany, Belgium, United States, South Africa
Novartis Pharmaceuticals

Completed

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDE225..

Normal Hepatic Function | Impaired Hepatic Function

Belgium, Germany, Israel, Bulgaria, United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function (HI)

Nonalcoholic Steatohepatitis (NASH)

United States
Novartis Pharmaceuticals

Completed

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Histologically-proven and Radiologically-confirmed Solid Tumors

Italy, New Zealand
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Terminated

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Array Biopharma, now a wholly owned subsidiary...

Terminated

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function (MEK162)

Hepatic Impairment

United States
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
ObsEva SA

Completed

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Participants

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

Liver Dysfunction

United States
Eli Lilly and Company
Algorithme Pharma Inc; CoLucid Pharmaceuticals

Completed

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

Migraine

United States, Canada
Gilead Sciences

Completed

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Long QT Syndrome

United States, Romania, New Zealand, Germany
Astellas Pharma Inc

Completed

Pharmacokinetics Study in Patients With Impaired Hepatic Function

Patients With Impaired Hepatic Function

Japan

3

Subscribe